API
CPPL / Products / API
Our APIs Products
GMP, GLP & ISO Approved Facility
| Sr. No. | Product Name | IH-DMF | Grade | Therapeutic Category | CAS Number | Know More |
|---|---|---|---|---|---|---|
| A OUR STRONG PRODUCT | ||||||
| 1 | Atorvastatin Calcium | √ | IP/BP/USP | Cardiovascular | 344423-98-9 | Know More |
| 2 | Azithromycin | IP/BP/EP/USP | Anti-Bacterial Infection | 117772-70-0 | Know More | |
| 3 | Dorzolamide | √ | IP/BP/EP/USP | Topical Beta Blockers | 130693-82-2 | Know More |
| 4 | Fluconazole | √ | IP/BP/USP | Anti-Fungal/Triazoles | 86386-73-4 | Know More |
| 5 | Montelukast Sodium | √ | IP/EP/USP | Anti-Asthmatic | 151767-02-1 | Know More |
| 6 | Nitrofurantoin | √ | IP/EP/USP | Antibiotic/Anti-Bacterial | 67-20-9 | Know More |
| 7 | Rosuvastatin Calcium | IP/BP/USP | Cardiovascular | 147098-20-2 | Know More | |
| 8 | Tadalafil | √ | IP/BP/USP | Erectile Dysfunction | 171596-29-5 | Know More |
| 9 | Tigecycline | √ | IP/BP/USP | Anti-Bacterial | 220620-09-7 | Know More |
| B OUR CAMPAIGN PRODUCT | ||||||
| 1 | Benfotiamine | IH | Diabetic Polyneuropathy | 22457-89-2 | Know More | |
| 2 | Citicoline Sodium | √ | IH/IP/USP | Nootropic, Psychostimulants | 33818-15-4 | Know More |
| 3 | Deferoxamine Mesylate | IP/BP/USP | Iron Chelating Agent | 138-14-7 | Know More | |
| 4 | Fexofenadine HCl | IP/BP/USP | Anti-Histamines | 153439-40-8 | Know More | |
| 5 | Mirabegron | EP/IH | Mirabegron : Sympathomimetic | 223673-61-8 | Know More | |
| 6 | Pantoprazole Sodium | IP/BP/EP/USP | Gastroesophageal Reflux Disease | 164579-32-2 | Know More | |
| C OUR RESEARCH & DEVELOPMENT PRODUCT | ||||||
| 1 | Brinzolamide | IP/BP/USP | Carbonic anhydrase inhibitor | 138890-62-7 | - | |
| 2 | Luliconazole | IP/BP/USP | Anti-Fungal | 187164-19-8 | - | |
| 3 | Pranlukast Sodium | IP/BP/USP | Anti-Asthmatic | 103177-37-3 | - | |
| 4 | Rivaroxaban | IP/BP/USP | Anti Coagulate | 366789-02-8 | - | |
| 5 | Vardenafil HCl | IP/BP/USP | Erectile Dysfunction | 330808-88-3 | - | |
Disclaimer: Patented products are available for R&D purposes only as permitted under 35 U.S.C section 271 (e) (I).